Alvotech’s Wessman Sets Out Next Steps On Biosimilars Journey
Founder And Chairman Robert Wessman Talks Partnerships, In-Licensing And Strategy
Alvotech ended 2021 by revealing major plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. In the first part of an exclusive two-part interview, founder and chairman Robert Wessman tells Generics Bulletin how the firm plans to move forward following the transaction.
